clinical trial · NCT03692676
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Boehringer Ingelheim·—·completed·n = 116,133
AsthmaSpiriva Respimat
brief summary
This study is a cross-sectional, non-interventional study based on existing data (NISed).
started
Mar 5, 2019
primary completion
Oct 11, 2019
completion
Oct 11, 2019
last updated
Apr 17, 2025
detailed description
The UK CPRD data will be used to assess the characteristics of asthma patients who were prescribed ICS/LABA FDC before the index date and who initiated Spiriva Respimat, or received a higher dose of ICS/LABA FDC, or initiated LTRA, or switched to a new ICS/LABA FDC in the UK during the study period (September 2014-December 2017) enabling to assess potential channeling of prescribing to different patient populations.
official title
Characteristics of Patients Initiating Spiriva Respimat in Asthma in the UK: a Cross-sectional Study Based on the Clinical Practice Research Datalink
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol